These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 34973391)

  • 1. TRIM29 regulates the SETBP1/SET/PP2A axis via transcription factor VEZF1 to promote progression of ovarian cancer.
    Qiao HY; Zhang Q; Wang JM; Jiang JY; Huyan LY; Yan J; Li C; Wang HQ
    Cancer Lett; 2022 Mar; 529():85-99. PubMed ID: 34973391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of Potential Alterations Affecting SETBP1 as a Novel Contributing Mechanism to Inhibit PP2A in Colorectal Cancer Patients.
    Torrejón B; Cristóbal I; Caramés C; Prieto-Potín I; Chamizo C; Santos A; Sanz-Alvarez M; Serna-Blasco R; Luque M; Madoz-Gúrpide J; Rojo F; García-Foncillas J
    World J Surg; 2018 Nov; 42(11):3771-3778. PubMed ID: 29796729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. m6A-YTHDF1-mediated TRIM29 upregulation facilitates the stem cell-like phenotype of cisplatin-resistant ovarian cancer cells.
    Hao L; Wang JM; Liu BQ; Yan J; Li C; Jiang JY; Zhao FY; Qiao HY; Wang HQ
    Biochim Biophys Acta Mol Cell Res; 2021 Jan; 1868(1):118878. PubMed ID: 33011193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression.
    Liu CY; Huang TT; Chen YT; Chen JL; Chu PY; Huang CT; Wang WL; Lau KY; Dai MS; Shiau CW; Tseng LM
    EBioMedicine; 2019 Feb; 40():263-275. PubMed ID: 30651219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of TRIM29 Alters Keratin Distribution to Promote Cell Invasion in Squamous Cell Carcinoma.
    Yanagi T; Watanabe M; Hata H; Kitamura S; Imafuku K; Yanagi H; Homma A; Wang L; Takahashi H; Shimizu H; Hatakeyama S
    Cancer Res; 2018 Dec; 78(24):6795-6806. PubMed ID: 30389700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The protein level of the tumour-promoting factor SET is regulated by cell density.
    Kohyanagi N; Kitamura N; Tanaka K; Mizuno T; Fujiwara N; Ohama T; Sato K
    J Biochem; 2022 Mar; 171(3):295-303. PubMed ID: 35076073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.
    Piazza R; Valletta S; Winkelmann N; Redaelli S; Spinelli R; Pirola A; Antolini L; Mologni L; Donadoni C; Papaemmanuil E; Schnittger S; Kim DW; Boultwood J; Rossi F; Gaipa G; De Martini GP; di Celle PF; Jang HG; Fantin V; Bignell GR; Magistroni V; Haferlach T; Pogliani EM; Campbell PJ; Chase AJ; Tapper WJ; Cross NC; Gambacorti-Passerini C
    Nat Genet; 2013 Jan; 45(1):18-24. PubMed ID: 23222956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TRIM29 promotes progression of thyroid carcinoma via activating P13K/AKT signaling pathway.
    Xu J; Li Z; Su Q; Zhao J; Ma J
    Oncol Rep; 2017 Mar; 37(3):1555-1564. PubMed ID: 28098872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. microRNA-761 induces aggressive phenotypes in triple-negative breast cancer cells by repressing TRIM29 expression.
    Guo GC; Wang JX; Han ML; Zhang LP; Li L
    Cell Oncol (Dordr); 2017 Apr; 40(2):157-166. PubMed ID: 28054302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TRIM29 regulates the p63-mediated pathway in cervical cancer cells.
    Masuda Y; Takahashi H; Hatakeyama S
    Biochim Biophys Acta; 2015 Oct; 1853(10 Pt A):2296-305. PubMed ID: 26071105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting inhibitors of the tumor suppressor PP2A for the treatment of pancreatic cancer.
    Farrell AS; Allen-Petersen B; Daniel CJ; Wang X; Wang Z; Rodriguez S; Impey S; Oddo J; Vitek MP; Lopez C; Christensen DJ; Sheppard B; Sears RC
    Mol Cancer Res; 2014 Jun; 12(6):924-39. PubMed ID: 24667985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tripartite motif-containing 29 (TRIM29) is a novel marker for lymph node metastasis in gastric cancer.
    Kosaka Y; Inoue H; Ohmachi T; Yokoe T; Matsumoto T; Mimori K; Tanaka F; Watanabe M; Mori M
    Ann Surg Oncol; 2007 Sep; 14(9):2543-9. PubMed ID: 17597343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RNA interference against TRIM29 inhibits migration and invasion of colorectal cancer cells.
    Xu W; Xu B; Yao Y; Yu X; Cao H; Zhang J; Liu J; Sheng H
    Oncol Rep; 2016 Sep; 36(3):1411-8. PubMed ID: 27430345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of TRIM29 suppresses cancer stem cell-like characteristics of PDACs via accelerating ISG15 degradation.
    Sun J; Yan J; Qiao HY; Zhao FY; Li C; Jiang JY; Liu BQ; Meng XN; Wang HQ
    Oncogene; 2020 Jan; 39(3):546-559. PubMed ID: 31501523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TRIM29 functions as a tumor suppressor in nontumorigenic breast cells and invasive ER+ breast cancer.
    Liu J; Welm B; Boucher KM; Ebbert MT; Bernard PS
    Am J Pathol; 2012 Feb; 180(2):839-47. PubMed ID: 22138580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The interaction of SET and protein phosphatase 2A as target for cancer therapy.
    Dacol EC; Wang S; Chen Y; Lepique AP
    Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188578. PubMed ID: 34116173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TRIM29 overexpression is associated with poor prognosis and promotes tumor progression by activating Wnt/β-catenin pathway in cervical cancer.
    Xu R; Hu J; Zhang T; Jiang C; Wang HY
    Oncotarget; 2016 May; 7(19):28579-91. PubMed ID: 27081037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer.
    Liu H; Gu Y; Wang H; Yin J; Zheng G; Zhang Z; Lu M; Wang C; He Z
    Oncotarget; 2015 Jun; 6(17):14913-25. PubMed ID: 25945834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TRIM29 functions as an oncogene in gastric cancer and is regulated by miR-185.
    Qiu F; Xiong JP; Deng J; Xiang XJ
    Int J Clin Exp Pathol; 2015; 8(5):5053-61. PubMed ID: 26191199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TRIM29 promotes antitumor immunity through enhancing IGF2BP1 ubiquitination and subsequent PD-L1 downregulation in gastric cancer.
    Jiang T; Xia Y; Li Y; Lu C; Lin J; Shen Y; Lv J; Xie L; Gu C; Xu Z; Wang L
    Cancer Lett; 2024 Jan; 581():216510. PubMed ID: 38029830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.